uBriGene
Miyun
About uBriGene
Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Total funding: $94.8M
- Funding stage: Late Stage Venture
- Last round: Series D (Dec 2024)
- Website: ubrigene.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/ubrigene-39680 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.